Literature DB >> 25616906

Activation of Nicotinic Receptors Inhibits TNF-α-Induced Production of Pro-inflammatory Mediators Through the JAK2/STAT3 Signaling Pathway in Fibroblast-Like Synoviocytes.

Tong Li1, Shiyao Wu, Huali Zhang, Yanping Wang, Hui Luo, Xiaoxia Zuo, Xianzhong Xiao.   

Abstract

It was recently demonstrated that stimulation of the nicotine receptor attenuates collagen-induced arthritis and inhibits cytokine release in mice. We elucidated the possible intracellular signaling mechanism of the cholinergic anti-inflammatory pathway in fibroblast-like synoviocytes (FLSs). Levels of interleukin (IL)-6, IL-10, and monocyte chemoattractant protein (MCP)-1 in culture supernatants of tumor necrosis factor (TNF)-α-stimulated FLSs were measured using an enzyme-linked immunosorbent assay (ELISA). FLSs were transfected with a small interfering RNA oligonucleotide (STAT3 siRNA or control siRNA). AG490, a specific inhibitor of JAK2, was added 16 h before nicotine, and blocker of nAChR was added 30 min before nicotine. Activation of signal transducers and activators of transcription (STAT) such as STAT1 and STAT3 were detected using Western blotting. Nicotine downregulated production of IL-6 and MCP-1 in RA-FLSs induced by TNFα in a concentration-dependent manner, and IL-10 levels were not significantly different after nicotine pretreatment. Nicotine-induced activation of STAT3 (but not STAT1) and deactivation of STAT3 decreased the anti-inflammatory effect of nicotine. AG490 inhibited the phosphorylation of STAT1 and STAT3 and decreased the TNF-α-induced production of pro-inflammatory mediators in RA-FLSs. A α7nAChR antagonist abrogated the anti-inflammatory effects of nicotine and suppressed STAT3 activity. In conclusion, nicotine has an anti-inflammatory effect on RA by downregulating production of IL-6 and MCP-1 in FLSs, and this is mediated through activation of the JAK2-STAT3 signal pathway.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25616906     DOI: 10.1007/s10753-015-0117-1

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  52 in total

Review 1.  Stats: transcriptional control and biological impact.

Authors:  David E Levy; J E Darnell
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

2.  Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2011-06-07       Impact factor: 54.908

Review 3.  STATs and gene regulation.

Authors:  J E Darnell
Journal:  Science       Date:  1997-09-12       Impact factor: 47.728

Review 4.  Pathogenesis of rheumatoid arthritis: targeting cytokines.

Authors:  Jochen Zwerina; Kurt Redlich; Georg Schett; Josef S Smolen
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

5.  The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles.

Authors:  Jörg H W Distler; Astrid Jüngel; Lars C Huber; Christian A Seemayer; Charles F Reich; Renate E Gay; Beat A Michel; Adriano Fontana; Steffen Gay; David S Pisetsky; Oliver Distler
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-08       Impact factor: 11.205

6.  Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis.

Authors:  A E Koch; S L Kunkel; L A Harlow; B Johnson; H L Evanoff; G K Haines; M D Burdick; R M Pope; R M Strieter
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

7.  TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.

Authors:  G Kobelt; K Eberhardt; P Geborek
Journal:  Ann Rheum Dis       Date:  2004-01       Impact factor: 19.103

8.  Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Akt.

Authors:  Michael V Volin; Nha Huynh; Karolina Klosowska; Kyle K Chong; James M Woods
Journal:  Arthritis Rheum       Date:  2007-08

Review 9.  The cholinergic anti-inflammatory pathway: towards innovative treatment of rheumatoid arthritis.

Authors:  Marjolein A van Maanen; Margriet J Vervoordeldonk; Paul P Tak
Journal:  Nat Rev Rheumatol       Date:  2009-04       Impact factor: 20.543

10.  Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues.

Authors:  Tineke C T M van der Pouw Kraan; Floris A van Gaalen; Pia V Kasperkovitz; Nicolette L Verbeet; Tom J M Smeets; Maarten C Kraan; Mike Fero; Paul-Peter Tak; Tom W J Huizinga; Elsbet Pieterman; Ferdinand C Breedveld; Ash A Alizadeh; Cornelis L Verweij
Journal:  Arthritis Rheum       Date:  2003-08
View more
  4 in total

1.  Inhibitory effect of baicalin on allergic response in ovalbumin-induced allergic rhinitis guinea pigs and lipopolysaccharide-stimulated human mast cells.

Authors:  Yun-Jiang Zhou; Hu Wang; He-Huan Sui; Li Li; Chun-Ling Zhou; Jia-Jun Huang
Journal:  Inflamm Res       Date:  2016-04-04       Impact factor: 4.575

2.  Naringin attenuates high glucose-induced injuries and inflammation by modulating the leptin-JAK2/STAT3 pathway in H9c2 cardiac cells.

Authors:  Changjun Luo; Xiao Ke; Si Xiong; Yun Sun; Qing Xu; Wei Zhang; Yiyan Lei; Yiqian Ding; Yulan Zhen; Jianqiang Feng; Fei Cheng; Jingfu Chen
Journal:  Arch Med Sci       Date:  2019-05-07       Impact factor: 3.318

Review 3.  Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects.

Authors:  Wenji Zhang; Hui Lin; Mingmin Zou; Qinghua Yuan; Zhenrui Huang; Xiaoying Pan; Wenjuan Zhang
Journal:  Front Immunol       Date:  2022-02-18       Impact factor: 7.561

4.  Kappa opioid receptor agonists improve postoperative cognitive dysfunction in rats via the JAK2/STAT3 signaling pathway.

Authors:  Xi Li; Yingjie Sun; Qiang Jin; Dandan Song; Yugang Diao
Journal:  Int J Mol Med       Date:  2019-09-13       Impact factor: 4.101

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.